\-\ Texto\\:\\ \ \(0\)\
\-\ bp\\ \\ 220\\/160\ \(0\)\
\-\ somnolent\\ and\\ hard\\ to\\ arouse\ \(0\)\
\-\ not\\ oriented\\ to\\ person\\,\\ place\\,\\ time\\.\ \(0\)\
\-\ with\\ anti\\-hypertensive\\ therapy\\ the\\ pathologic\\ changes\\ on\\ follow\\-up\\ ct\\ resolved\ \(0\)\
\-\ low\\ attenuation\\ changes\\ on\\ ct\\ involving\\ the\\ occipital\\ and\\ posterior\\ parietal\\ lobes\\.\ \(0\)\
\-\ posterior\\ reversible\\ leukoencephalopathy\\,\\ pres\ \(0\)\
\-\ posterior\\ reversible\\ encephalopathy\\ syndrome\ \(0\)\
\-\ cerebral\\ infarction\ \(29\)\
\-\ encephalitis\ \(55\)\
\-\ this\\ 37\\ y\\.o\\.\\ man\\ presents\\ with\\ somnolence\\ and\\ markedly\\ elevated\\ blood\\ pressure\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ reversible\\:\\ 0\\.17613772217255946\ \(0\)\
\-\ 220\\/160\\:\\ 0\\.13562336036871536\ \(0\)\
\-\ arouse\\:\\ 0\\.12495955759087005\ \(0\)\
\-\ anti\\-hypertensive\\:\\ 0\\.11872163285074444\ \(0\)\
\-\ somnolent\\:\\ 0\\.11429575481302474\ \(0\)\
\-\ somnolence\\:\\ 0\\.11086277710049844\ \(0\)\
\-\ pres\\:\\ 0\\.0939610495825275\ \(0\)\
\-\ leukoencephalopathy\\:\\ 0\\.09115610255492822\ \(0\)\
\-\ posterior\\:\\ 0\\.09090639455549764\ \(0\)\
\-\ person\\:\\ 0\\.08491817781480261\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.07740505830843442\ \(0\)\
\-\ changes\\:\\ 0\\.07535532234569417\ \(0\)\
\-\ encephalitis\\:\\ 0\\.07342257163279921\ \(0\)\
\-\ hard\\:\\ 0\\.07237914707374134\ \(0\)\
\-\ 37\\:\\ 0\\.06605738226026858\ \(0\)\
\-\ oriented\\:\\ 0\\.06446993247203427\ \(0\)\
\-\ place\\:\\ 0\\.06387814353622202\ \(0\)\
\-\ resolved\\:\\ 0\\.06373368599237833\ \(0\)\
\-\ markedly\\:\\ 0\\.062228212300012825\ \(0\)\
\-\ occipital\\:\\ 0\\.06134161056406458\ \(0\)\
\-\ lobes\\:\\ 0\\.05793326794949171\ \(0\)\
\-\ pathologic\\:\\ 0\\.057543763211271866\ \(0\)\
\-\ bp\\:\\ 0\\.057070353077937196\ \(0\)\
\-\ parietal\\:\\ 0\\.05616511461604592\ \(0\)\
\-\ infarction\\:\\ 0\\.05373089915120138\ \(0\)\
\-\ attenuation\\:\\ 0\\.052855708775785215\ \(0\)\
\-\ pressure\\:\\ 0\\.05162973707418984\ \(0\)\
\-\ involving\\:\\ 0\\.0461293425231276\ \(0\)\
\-\ cerebral\\:\\ 0\\.045545330796370326\ \(0\)\
\-\ elevated\\:\\ 0\\.04460486709783174\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.04276979986833449\ \(0\)\
\-\ y\\.o\\:\\ 0\\.03794429896287231\ \(0\)\
\-\ syndrome\\:\\ 0\\.037598562718994484\ \(0\)\
\-\ time\\:\\ 0\\.0371323265729125\ \(0\)\
\-\ ct\\:\\ 0\\.0367785739505244\ \(0\)\
\-\ low\\:\\ 0\\.036556431582559994\ \(0\)\
\-\ blood\\:\\ 0\\.03588324726937384\ \(0\)\
\-\ therapy\\:\\ 0\\.03514831994216328\ \(0\)\
\-\ man\\:\\ 0\\.031091259124461527\ \(0\)\
\-\ presents\\:\\ 0\\.026856066084737323\ \(0\)\
\-\ on\\:\\ 0\\.02227356961124394\ \(0\)\
\-\ not\\:\\ 0\\.018997210334491314\ \(0\)\
\-\ this\\:\\ 0\\.01478672635867897\ \(0\)\
\-\ to\\:\\ 0\\.013140557182861116\ \(0\)\
\-\ \\,\\:\\ 0\\.012494310716182495\ \(0\)\
\-\ and\\:\\ 0\\.00830810795687162\ \(0\)\
\-\ the\\:\\ 0\\.004253824144726948\ \(0\)\
\-\ with\\:\\ 0\\.0036001284950735305\ \(0\)\
\-\ \\.\\:\\ 0\\.002184586836759771\ \(0\)\
